colorectal cancer by the numbers - bms.com · colorectal cancer by the numbers colorectal cancer,...
TRANSCRIPT
COLORECTAL CANCER BY THE NUMBERSCOLORECTAL CANCER, OR CRC, IS THE 3RD MOST COMMONLY DIAGNOSED CANCER IN THE WORLD.
WORLDWIDE INCIDENCE IS EXPECTED TO INCREASE FROM 1.8 MILLION CASES DIAGNOSED IN 2018 TO 3.1 MILLION CASES BY 2040.
1,026,000
823,300
CRC MORE COMMON
IN MEN THAN WOMEN
MEDIAN AGE
67
73
AT DIAGNOSIS
AT DEATH
Source: American Cancer Society 2018
STAGING & SURVIVAL RATES
5-YearRelativeSurvivalRates
THERE ARE FOUR STAGES OF CRC. PATIENTS WITH
ADVANCED FORMS OF THE DISEASE HAVE FEWER
TREATMENT OPTIONS & LOWER SURVIVAL RATES.
RATES VARY GLOBALLY,
DEPENDING ON THE STAGE AND
TYPE OF COLORECTAL CANCER:
COLON CANCER RECTAL CANCER
92% 88%
81% 83%
13%
87% 90%
12%
STAGE I
STAGE I I
STAGE I I I
STAGE IV
STAGE I
STAGE I I
STAGE I I I
STAGE IV
53%
65%
50%
58%
LOW HIGH
COMMON RISK FACTORS
HEAVYALCOHOL USE
SMOKINGOBESITY
AGEOVER 50
FAMILYHISTORY
PHYSICALINACTIVITY
50+
WEAKNESS AND FATIGUE
UNINTENDED WEIGHT LOSS
CHANGE IN BOWEL HABITS(SUCH AS DIARRHEA& CONSTIPATION)
RECTAL BLEEDING
BLOOD IN THE STOOL
CRAMPING OR ABDOMINAL PAIN
SIGNS & SYMPTOMSTREATMENT OPTIONS
SURGERY RADIATIONTHERAPY
TARGETEDTHERAPY
© 2018 Bristol-Myers Squibb Company
ESTIMATED NUMBERS OF ANNUAL NEW CRC CASES BY REGION (THOUSANDS)
EUROPE499.6
CENTRAL AMERICA19.5
SOUTH AMERICA97.6
AFRICA61.8
AUSTRALIA & NEW ZEALAND21.2
COLORECTAL CANCER “HOT SPOTS”
NORTH AMERICA179.7
ASIA957.9
Source: Globocan 2018
CRC OFTEN BEGINS AS A GROWTH CALLED
A POLYP, WHICH MAY FORM ON THE INNER
WALL OF THE COLON OR RECTUM.
MICROSATELLITE INSTABILITY HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENT (dMMR) CRC
SOME CASES OF CRC ARE MSI-H OR dMMR, WHICH OCCURS WHEN THERE ARE
DEFICIENCIES IN THE CELL'S ABILITY TO REPAIR DNA ERRORS DURING CELL DIVISION.
5-YEAR SURVIVAL RATE RANGE:
APPROXIMATELY 15%
OF ALL PATIENTS
WITH CRC HAVE MSI-H
OR dMMR TUMORS.
ABOUT 4-5% OF PATIENTS
WITH METASTATIC CRC HAVE
MSI-H OR dMMR TUMORS.
PATIENTS WITH MSI-H OR dMMR METASTATIC CRC TYPICALLY HAVE A POOR PROGNOSIS WITH
LOWER SURVIVAL RATES COMPARED TO PATIENTS WHOSE TUMORS ARE NOT MSI-H OR dMMR.
A PATIENT’S TREATMENT OPTIONS
ARE LARGELY DEPENDENT ON STAGE
OF DISEASE, AND IN SOME CASES
BIOMARKERS, AND MAY INCLUDE:
CHEMOTHERAPY IMMUNOTHERAPY
WHAT IS CRC?
CRC IS A CANCER THAT FORMS IN THE TISSUES OF THE COLON OR RECTUM,
WHICH ARE PART OF THE BODY’S DIGESTIVE OR GASTROINTESTINAL (GI) SYSTEM.